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Vanishing bone disease is a very rare, peculiar destructive condition of the skeletal system resulting in spontaneous 
and progressive resorption and disappearance of osseous structures with replacement by vascular, fibrous connecti-
ve tissue. Children and adolescents are most commonly affected, although patients ranging in age from 18 months 
to 40 years have been reported. Its clinical presentation is highly variable largely depending upon the site of ske-
letal involvement. The maxillofacial territory and upper extremity bones are the predominant sites affected by this 
ailment. The etio-pathogenesis of this condition still remains poorly understood, the natural history and prognosis 
is unpredictable. Radiographic findings associated with vanishing bone disorder are particularly dramatic and cha-
racterized by complete resorption and disappearance of the affected bone leading to the definition of “vanishing 
bone” or “disappearing bone disease.”  Although various treatment options have been suggested, in general, no 
single treatment modality has proven effective in arresting this rare clinical entity. The present article provides an 
insight into the in-depth comprehensive review of literature pertaining to this fascinating musculoskeletal disorder 
in children.
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Introduction
“Vanishing bone disease” is an extremely rare idiopathic 
disease entity affecting the musculoskeletal system and 
characterized by extensive loss of bony matrix which is 
replaced by proliferating thin-walled vascular channels 
and fibrous tissue (1,2). The radiographic features asso-
ciated with this condition are particularly dramatic be-
cause in most of the cases, a complete resorption and di-
sappearance of the affected bone occurred, and hence the 
terms “vanishing bone disease” or “disappearing bone 
disease” or “phantom bone” has been applied (1,3). 
Most cases of vanishing bone disorder occurred in chil-
dren or in adults less than 40 years of age (4-7). Howe-
ver, the disease has been described in patients as young 
as one month to as old as 75 years (4,5). The bones of the 
maxillofacial region and upper extremity are the predo-
minant osseous locations of this disease (6). In decrea-
sing order of frequency it affects the mandible, scapula, 
proximal end of humerus, femur, rib, iliac bone, ischium 
and sacrum, although no area of the skeleton is immune. 
Mandible is the most common site of osteolysis in maxi-
llofacial territory (6-8). 
Still the precise etiology of this disorder remains poorly 
understood. There is no evidence of a malignant, neuro-
pathic or infectious component involved in the causation 
of this disease and mechanism behind bone destruction 
or resorption is unclear. This rare disorder is not asso-
ciated with gender or racial predilection too. However, 
approximately 60% of all cases with vanishing bone di-
sease occurred in men (9). A variety of imaging methods 
have been used in evaluating patients suspected of ha-
ving vanishing bone disease such as plain radiographs, 
radioisotope scans, computed tomography (CT), scinti-
graphy and magnetic resonance imaging (MRI) (6-13). 
But there is no consensus to date regarding the definite 
treatment for this condition. The suggested treatment 
strategies include surgical intervention, chemotherapy 
and radiation therapy. However, in general, no single 
treatment modality has proven effective in arresting the 
disease (10). 
All previously reported cases involving the maxillofa-
cial region have affected the mandible alone or with the 
maxilla or maxilla alone (3,4,8,11-15). The clinical pre-
sentation is variable, and in the jaws, pain, tooth mobility, 
pathological fracture, facial deformity and malocclusion 
are early signs encountered (13-15). When vanishing 
bone disease involves the jaws of children, the role of 
pediatric dentist is extremely important in diagnosing 
promptly the disorder and preventing the functional 
and aesthetic consequences of advanced and extensive 
bone loss. Furthermore, mandibular involvement is con-
sidered a potential high-risk disease location, as severe 
progression from mandible to maxilla, skull and spine 
has been reported, thus leading to poor prognosis (11-
13). Accordingly, an early diagnosis of vanishing bone 
disease of the maxillofacial region is crucial to prevent 
patient’s morbidity and mortality, and seems to be feasi-
ble because of the presence of early signs such as teeth 
mobility and bone loss. 
The prognosis of vanishing bone disease is highly varia-
ble and unpredictable, ranging from minimal disability 
to death, because of the involvement of vital structures 
(16). Even if the osteolytic process often arrests spon-
taneously, the involvement of vital structures, such as 
the vertebral column and rib cage, is able to cause dea-
th (1,2,6). The course of the disease is particularly in-
sidious, as the osteolytic process is typically painless, 
allowing normal patient activity to continue while bone 
destruction occurs, making the patients susceptible to 
pathologic fractures (16). 
Numerous articles on vanishing bone disease with di-
fferent synonyms are published including both medical 
and dental disciplines like orthopaedic surgery, medici-
ne, general surgery, otolaryngorhinology, neurosurgery, 
plastic surgery and maxillo-facial surgery (1-16). On 
comprehensive review of dental literature, it is evident 
that an overview of this rare disorder of the musculoske-
letal system in pediatric field is not available. Each child 
suffering from vanishing bone disorder is unique and 
clinical presentation, and treatment varies individually, 
so the role of pediatric dentist is of utmost important 
in diagnosing the disorder and for early referral to re-
ceive comprehensive treatment and thereby preventing 
the complications. The aim of this review article is to 
make the pediatric dental fraternity aware of this rare 
mysterious disorder and discuss the pathogenesis, cli-
nical symptoms, investigations, diagnosis, differential 
diagnoses and various treatment options for children su-
ffering from vanishing bone disease. 
Review of literature   
Synonyms 
Numerous names have been used in the world literature 
to describe this rare disorder such as Gorham’s disease, 
Gorham-Stout syndrome, phantom bone disease, mas-
sive osteolysis, disappearing bone disease, acute spon-
taneous absorption of bone, hemangiomatosis, essential 
osteolysis and lymphangiomatosis, Gorham’s vanishing 
bone disease, thoracic lymphangiomatosis, vanishing 
bone tumor, Gorham’s syndrome, idiopathic massive os-
teolysis, massive Gorham osteolysis, Morbus Gorham-
Stout disease, progressive massive osteolysis, dissemi-
nated lymphangiomatosis, Hajdu-Cheney syndrome, 
idiopathic multicentric osteolysis, Acro-osteolysis syn-
drome, lymphangiomatosis-hepatic disease, lymphan-
giomatosis-splenic disease, cystic angiomatosis of bone, 
and diffuse pulmonary lymphangiomatosis (6-20).
Historical perspective
Idiopathic osteolysis was first described in 1838 (16) 
and with term “vanishing bone disease” was first des-
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suggested that a previous silent hamartoma can become 
active after a minor trauma, leading to bone resorption. 
Heyden and colleagues (28) found strong activity of 
both acid phosphatase and leucine aminopeptidase in 
mononuclear periavascular cells that were in contact 
with remaining bone, perhaps indicating that these cells 
are important in the process of osseous resorption. 
According to Thompson and Schurman (29), the disease 
is a primary aberration of vascular tissue in bone, related 
to hyperemic granulation tissue. Young et al (30) sta-
ted endothelial dysplasia of blood and lymphatic vessels 
could lead to osteolysis. Osteoclasts are the only cells 
capable of resorbing bone. Therefore, it is presumed 
that vanishing bone disease may represent a pathologic 
derangement of osteoclastic activity. Any defect of the 
osteoclasts could lead to idiopathic osteolysis. It has also 
been suggested that thyroid c cells and calcitonin may 
play an important role in the pathogenesis of this con-
dition (31). 
Clinical presentation and symptoms
Clinical onset of vanishing bone disease has been re-
ported to occur anytime from childhood to adulthood 
and has been noted to be posttraumatic in many cases 
(4-7,32). It usually manifests unilaterally and includes 
focal lymphatic proliferation involving one bone or con-
tiguous bones such as vertebrae. Adjacent soft tissue 
can also be involved, producing diffuse muscle atrophy. 
Any part of the skeleton can be affected and the process 
may affect the appendicular or the axial skeleton (33). 
The shoulder and the maxillofacial region are the most 
common sites of involvement (6-8,11,12,33); however, 
various locations such as the humerus, scapula, clavicle, 
ribs, sternum, pelvis and femur can be affected by va-
nishing bone disease. The disorder is also known to oc-
cur at other sites such as the skull, spine, hand and foot 
(34). If the shoulder girdle or thoracic cage is involved, 
then 17% of patients develop chylothorax which leads to 
hypoproteinemia, malnutrition and immunosuppression; 
this is often fatal with a mortality rate of 64% (35,36).
Clinical manifestations of vanishing bone disease may 
vary and depend on the affected site (6). Dull aching, 
swelling, weakness in the affected extremity, and skele-
tal deformities are prominent symptoms, whereas, some 
patients presented with a history of insidious onset of 
pain, limitation of motion, and progressive weakness 
in the involved limb.  The usual presenting symptom is 
localized pain usually secondary to fracture. However, 
deformity of bone may be the only complaint as reported 
in some cases (6-8,11-15,36). 
Vanishing bone disease in the maxillofacial territory
Among the 200 vanishing bone disorder cases reported 
in the international literature, approximately 50 cases 
have been found to affect bones of the maxilla-facial re-
gion (usually the mandible) (6-8,11,12). The first case 
reported in the jaws was by Romer (37) in 1924, in a 
cribed by J.B.S. Jackson in 1872 in a 12-year-old boy 
having complete osteolysis of the humerus (20). The cli-
nical features were so impressive that which provoked 
the author to describe the case as the “Boneless arm” 
(16) Since then approximately 200 cases of vanishing 
bone disease affecting various skeletons has been re-
ported in the literature. In 1954, Gorham and colleagues 
(21) presented two patients affected by this condition. 
Of the two cases, one was a 16-year-old boy with right 
clavicle and scapula involvement. This patient eventua-
lly developed chylothorax, a serious complication of va-
nishing bone disease and finally expired. The other pa-
tient was 44-years-old male, who also had involvement 
of the right clavicle and scapula. In addition to these two 
cases, they reported a review of 16 cases with this con-
dition. Later in 1955, Gorham and Stout1 published the 
first overview of vanishing bone disorder and reported 
24 additional cases. They further characterized the main 
pathologic features of this disease as non-malignant in-
traosseous proliferation of vascular tissue that caused 
massive osteolyis.  Hence vanishing bone disease is also 
well known as “Gorham’s disease.” 
Vanishing bone disease during pregnancy has been re-
ported in 1993 by Porter et al (22). The infant was deli-
vered by forceps, with a good outcome. Two other cases 
of this condition with natural pregnancies were also pre-
sented by Kulenkampff et al (23).
Etiopathogenesis and pathophysiology 
The exact etiology and the mechanism behind bone des-
truction and resorption in vanishing bone disease is still 
unknown. There is no genetic transmission and the inci-
dence of the disease may be linked to a history of minor 
trauma (16,20).
The pathological process involves the replacement of 
normal bone by an aggressively expanding but non-
neoplastic vascular tissue (24,25). It is unknown what 
stimulus sets off this change in bone and also whether 
all bones of the affected individual are equally likely to 
react in this adverse fashion. Since it is most commonly 
seen with trauma (16,20), it is reasonable to deduce that 
the traumatic episode initiates the sequence of events. 
Since neovascularisation of the blood clot that forms in 
between fragments of a fracture is the first step in bone 
healing it is tempting to speculate that some error in this 
process, or in the control of this process, is the root cause 
of vanishing bone disease. 
Campbell (26) hypothesized that post-traumatic arterial 
hyperemia was responsible for bone resorption, but this 
was rejected by Gorham et al (21). The same author pos-
tulated an angioma might act as a shunt, thereby increa-
sing local oxygen tension (21). In most cases, trauma 
was relatively trivial, and in some cases, trauma did not 
occur (6). As with many other diseases, the role of trau-
ma in vanishing bone disease may be to signal the pre-
sence of a preexisting abnormality. Whereas Knoch (27) 
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31-year-old woman. Frederiksen et al (13) observed that 
the mandible is involved most frequently, followed by 
the maxilla with varying degrees of involvement of con-
tiguous structures including the hard palate, sphenoid 
bone, and zygomatic bone.
Initial presentation of vanishing bone disorder with 
maxillofacial involvement may be evident as mobile 
but vital teeth with accompanying gingival hemorrhage. 
Hypoplasia, pain, malocclusion, and resorption of the 
affected alveolar and adjacent bone are other features 
(6-8,11,12,38-40). Involvement of the temporomandi-
bular joint by vanishing bone disease can be mistaken 
for temporomandibular dysfunction and mandibular 
involvement may present as pathological fracture (41). 
Maxillofacial involvement, seen first with pain, ma-
locclusion and deformity, is reported in 30% of cases 
(42). Jaw bone involvement can also affect mastication, 
swallowing, speaking, and respiratory function, as well 
as cosmetic appearance of the affected child. 
Investigations and diagnosis 
The diagnosis of vanishing bone disease is based on 
thorough clinical examination, radiologic imaging stu-
dies, and histopathologic examination of the affected 
bone (6,13,24,33). The standard laboratory findings are 
not specific and of no value in diagnosis of this condi-
tion (24). An elevated serum alkaline phosphatase level 
has been reported in some patients with an associated 
fracture (6). A variety of imaging methods such as plain 
radiographs, radioisotope scans, computed tomography 
and magnetic resonance imaging (32) have been used 
in evaluation of patients with vanishing bone disorder 
(24,31,43).
Devlin et al (25) also showed increased levels of inter-
leukin-6 might act as a potential mediator of increased 
osteoclast activity in patients with vanishing bone di-
sease. Assoun et al (44) used computed tomography to 
differentiate soft-tissue involvement and the extent of 
bone osteolysis and also to facilitate biopsy of the affec-
ted bone. Radioisotope bone scan may demonstrate in-
creased vascularity on initial images and subsequently, 
an area of decreased uptake corresponding to the site of 
diminished or absent osseous tissue (24,43). However, 
these results have been found variable. Conventional an-
giography could not reveal the pathologic vascular chan-
ges according to Szabo and Habre (45), and scintigraphy 
(43) is not reliable because of variable accumulation of 
isotopes at the lesion site. MRI findings of this condition 
are non-specific and variable. T1 weighted spin echo 
MRI shows uniform low signal intensity in involved 
bones, whereas increased signal intensity shows in T2 
weighted spin echo images (43,44).
Radiographic findings  
The most dramatic feature of vanishing bone disorder 
is its radiographic appearance (1-3,13,43). Naden (46) 
in 1995, suggested radiographs are the best tools for de-
tecting vanishing bone disease. Radiographic findings in 
patients with this disease were well described by Res-
nick (47). 
During initial stage of the lesion radiolucent foci appear 
in the intramedullary or subcortical regions, resembling 
findings seen in patchy osteoporosis. Subsequently, 
slowly progressive atrophy, dissolution, fracture, frag-
mentation and disappearance of a portion of the bone oc-
curs with tapering or pointing of the remaining osseous 
tissue and atrophy of soft tissues. The disease process can 
extend to contiguous bones; the intervening joints afford 
no protection to extension of the disease (1-3,43).
Patrick in 1976 (48) classified radiological changes of 
vanishing bone disease into four stages as: 
Radiolucent foci, resembling patchy osteoporosis
Shrinkage of shaft of bones by tapering of the ends 
(“Sucked candy” appearance)
Complete resorption of the bone unless there is spon-
taneous arrest and Progression to adjacent bones and 
joints 
Histo-pathological features 
Histo-pathological examination of tissue from an affec-
ted area in vanishing bone disease reveals a non-specific 
vascular proliferation with fibrous connective tissue, 
sometimes containing lymphocytes and plasma cells 
(13,24). The vascular proliferation consists of thin-
walled, often dilated, vascular or lymphatic channels of 
varying sizes (6). Angiomatosis, however, is not always 
a histopathological feature and has been questioned in 
the literature as an intrinsic characteristic. 
 Histological diagnosis depends on the phase in which 
the disease is diagnosed. Heffez et al (49) in 1983, des-
cribed 2 phases of this disease. In the first phase, increa-
sed vascular concentration in the bone-displacing fibrous 
tissue part is seen; and the second phase represents only 
fibrous tissue. The presence and number of osteoclasts 
vary significantly in vanishing bone disease.  In most re-
ported cases the osteoclastic activity was minimal or no-
nexistent, whereas in other cases, osteoclasts were easily 
identifiable. If present, osteoclastic activity is seen in the 
interface between the vascular channels and the cortex.
Heffez et al (49) suggested eight criteria (histopatho-
logic and clinical) for definitive diagnosis of vanishing 
bone disease which help distinguish from other destruc-
tive bone disorders as follows: 
Positive biopsy in terms of angiomatous tissue pre-1. 
sence
Absence of cellular atypia2. 
Minimal or no osteoclastic response and absence of 3. 
dystrophic calcification 
Evidence of local bone progressive resorption4. 
Non-expansive, non-ulcerative lesion 5. 
Absence of visceral involvement 6. 
Osteolytic radiographic pattern and7. 
Negative hereditary, metabolic, neoplastic, immu-8. 
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nologic and infectious etiology 
Differential diagnosis 
For differential diagnosis of vanishing bone disease in 
chidlren, other causes of osteolysis should be considered 
such as hereditary osteolysis, skeletal angiomas, essen-
tial osteolysis, trauma (Sudeck atrophy), infection, en-
docrine diseases, various nervous system diseases, and 
malignancies (primary or secondary) (6,47,50). In all of 
the other disorders, the histologic and clinical features 
are distinct from vanishing bone disease.    Essential 
osteolysis causes resorption of carpal and tarsal bones 
with progressive renal failure but without vascular proli-
feration (33). Skeletal angiomas have less growth poten-
tial and tend to preserve bony cortex without spreading 
into adjacent bone. In hereditary osteolysis the disease 
process starts in childhood, tends to be multicentric, and 
involves primarily the hands and foot (carpotarsal osteo-
lysis) but vascular proliferation is not seen. Malignant 
disease must be ruled out histologically, although lack 
of soft tissue mass points away from the presence of a 
neoplasm. Sclerosis and periosteal bone formation, seen 
radiographically in osteomyelities, are not features of 
vanishing bone disease. There are no serum abnorma-
lities or generalized osseous changes as with metabolic 
conditions (33,37,47). 
Therefore, it is worth emphasizing that for all children 
who present with skeletal osteolysis, a thorough history 
and meticulous physical examination should be under-
taken first. Appropriate blood test and radiographic stu-
dies should be made mandatory to rule out other com-
mon underlying causes of osteolysis in children. 
Management 
Extensive review of current literature showes that there 
is no universally accepted, most efficacious treatment for 
vanishing bone disease. The goal of the treatment is to 
arrest progression of the osteolysis as remineralization 
or reformation of affected bone is not seen. Therapeutic 
treatment with estrogens, magnesium, calcium, vitamin 
D and vitamin B12, fluoride, and calcitonin as well as 
cisplatin, actinomycin D, aluminium acetate solution, 
ultraviolet radiation, somatotrophin, amino acids, or 
even placental extracts or transfusions of placental blood 
have been tried and proved unsuccessful (6,33). Anavi et 
al (11) suggested treatment for vanishing bone disorder 
should include surgery, radiotherapy and various medi-
cations, either alone or in combination. 
Surgical intervention has been proposed as the method 
of choice by many authors that involve local resection of 
the affected bone and reconstruction using bone grafts 
and or prostheses (51-53). But bone grafting techniques 
have yielded poor results, and many authors observed 
a high incidence of bone graft resorption (52). Sympa-
thectomy also has been suggested but with no effect on 
the disease (6). Immobilization of the involved extremi-
ty does not affect the prognosis (33). In children with 
spinal involvement, instability must be watched for and 
managed early. Spinal localizations are best treated by 
segmental fixation extended to normal vertebrae (6). 
Apart from standard orthopaedic treatment for fractu-
res, non unions and deformities, the medical treatment 
for vanishing bone disease can be categorized into two 
groups; chemotherapy (anti-osteoclastic medication like 
bisphosphonates and alpha-2b-interferon) and radiation 
therapy (6,33). Chemotherapy has been advocated to be 
successful in some cases (6,33,54). 
Radiotherapy acts by accelerating sclerosis of the pro-
liferating blood vessels and prevents re-growth of these 
vessels. Results obtained with radiation therapy have 
been equivocal, although in few patients, apparent arrest 
has been produced. Radiation therapy, especially when 
used early in the course of the disease, appears to be the 
only accepted form of treatment with a greater chance of 
success. However, it is difficult to determine the potential 
of radiation therapy accurately as its use in the treatment 
of vanishing bone disease has been documented as only 
case reports (6,33,55,56). It is reported that the use of to-
tal doses from 30 to 45 Gy are most effective. Fontanesi 
(55) showed excellent results using a total dose of 15 Gy 
in a case that involved the upper extremity. Hanly et al 
(56) reported rapid relief of symptoms and prevention 
of further osseous destruction during a 6-year follow-
up period with a total dose of 3000 rads. Re-growth of 
bone after radiation therapy is unusual but has been re-
ported in some patients (26,57). Radiation therapy can 
be used for the management of chylothorax and pleural 
effusion in cases who may not be suitable candidates for 
an extensive surgical procedure due to their poor general 
health, and for those who have failed surgical treatment 
(58,59). However, the disadvantages of radiation thera-
py including the possibility of acute side effects such as 
gastrointestinal tract irritation with resultant nausea and 
or vomiting, and radiation induced pneumonia should be 
considered. Other treatment options that have been used 
effectively for the management of chylothorax are pleu-
rodesis, pleurectomy, thoracic duct ligation, oral clo-
dronate, bleomycin and interferon alfa-2b therapy (48). 
Of course, the usefulness of all these treatments is also 
shaped by the severity of the disease (for example, sur-
gery would be impractical in patients with widespread 
vertebral involvement) and the urgency of the patient’s 
condition (36). 
In children and adolescents when considering radiothe-
rapy the complications like potential for secondary ma-
lignant transformation, growth restrictions and damage 
to tooth formation and eruption should be considered 
before embarking on this mode of treatment (6,7,18). 
Prognosis 
The prognosis of vanishing bone disease varies from 
slight disability to death due to involvement of vital 
skeletal structures, malnutrition, lymphocytopenia or 
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infection (6). It has been reported that more than 15% 
of patients die as a result of their disease. Severe disabi-
lity occurs due to involvement of the pelvis, thorax, and 
cervical spine (52). Neurological complications increase 
the mortality of this condition to 33.3%. However, the 
disease usually remains localized within a skeletal re-
gion and undergoes eventual spontaneous arrest. In pa-
tients complicated with chylothorax, the mortality rate is 
more than 50% (36,48,59). Of 22 reported cases of this 
condition related chylothorax between 1960 to 2000, 12 
patients survived and 10 were died. Of the 12 surviving 
patients, 8 were surgically managed and 4 were medica-
lly managed, all in a trial and error basis (36,48,59). 
New ray of hopes 
Due to the rarity of the disease and non-availability of 
most efficacious treatment options, recently research 
has begun on genetic mechanisms in treating vanishing 
bone disease (6,33). A vascular endothelial growth fac-
tor receptor (VEGRr3) that is specific for lymphatics has 
been identified. Three genes associated with inherited 
lymphedema have also been discovered. Animal models 
simulating lymphedema are currently being studied. It 
is possible that the pathogenesis of lymphangiomatosis 
and vanishing bone disease is different; lymphatic mal-
formations that arise during early childhood might stem 
from aberrant sequestrations of lymphatic vessels, while 
the acquired proliferation of small lymphatics observed 
in vanishing bone disease might be driven by lymphan-
giogenic growth factors. 
Complications 
Complications of vanishing bone disease may be neu-
rological or pulmonary and they usually depend on the 
affected bones (60,61). Chylothorax and hemothorax 
also may be associated with this condition (48,60,61). 
Because there have been 25 reported cases of chylo-
thorax as a complication of vanishing bone disease in 
that 10 cases were bilateral (6,33,48). Chylothorax can 
be resulted from invasion of the thoracic duct by the 
lymphangioma or penetration of vascular dysplasia into 
the pleural cavity (35,48). Paraplegia related to spinal 
cord involvement may occur in patients who have in-
volvement of vertebrae with resultant osteolysis (6,62). 
Thoracic cage, pulmonary, or pleural involvement can 
lead to compromise of respiratory function and death 
can ensue (6,61,62). Infections of bone and septic shock, 
although rare, have also been reported (58). 
Discussion  
Vanishing bone disease is a combined clinical, radiogra-
phic and histologic entity characterized by benign vascu-
lar proliferation originating in bone and producing com-
plete lysis of all or a portion of the bone. This condition 
can involve men or women and any age group although 
most cases are reported before the age of 40 years (4-7). 
There is no biochemical or endocrine abnormality asso-
ciated with the condition. The skeletal structures affec-
ted include the thorax, hip bones, spine, maxilla and 
mandible although no area of the skeleton is immune. 
This condition does not occur often enough to be recog-
nized early and take many years for the condition to be 
recognized even though it is quite well described (6-8, 
11-13). In most cases, the condition is not recognized 
until a fracture occurs following trivial trauma and bone 
healing is delayed or subverted (25,63). There are no 
reported cases of metastasis to date, although polyosto-
tic and monostotic lesions have been described (64). In 
some cases, the disease has spontaneously arrested and 
in others progression of disease has resulted in death of 
the patient (6). Clinically the course of this disease is 
divided into two phases, an active phase of bone resorp-
tion and lysis and a second, generally dormant phase 
(13,33). The succession of phases is unpredictable, ta-
king a few months to many years. Chylothorax and pleu-
ral effusions may occur due to mediastinal extension of 
the disease process from the involved vertebra, scapula, 
rib or sternum and can be life threatening (48,60,61). A 
high morbidity and mortality is seen in patients with spi-
nal and or visceral involvement. 
The etiology of this condition still remains unknown, 
although an initial trauma, or modification in local con-
ditions such as variation of PH, inflammations are sus-
pected (16,20,24,25). Histologically bone is replaced 
by abundance of thin-walled, capillary-sized vascular 
channels and at a later stage by fibrous connective tissue 
(13,24). Diagnosis of vanishing bone disease is often de-
layed and most difficult in majority cases as laboratory 
findings are found within normal limits. So a high index 
of clinical suspicion together with characteristic radio-
graphic and histopathological findings is more helpful 
for making an early diagnosis. 
Imaging features of vanishing bone disease on conven-
tional radiography, CT and MRI have been reported in 
the literature and most of the cases failed to show the 
vasculature entity of the lesion an important pathologic 
feature of the disease (1-3, 13,24,32,43). On radiogra-
phs, vanishing bone disease appears as unilateral, partial 
or total disappearance of contiguous bones, tapering of 
bony remnants, and absence of a sclerosing or osteoblas-
tic reaction. Pertinent negative radiographic findings are 
absence of phleboliths, vascular or soft-tissue calcifica-
tion, coarse trabeculation, and any related bony abnor-
mality with the exception of demineralization resulting 
from disuse. 
Due to the rarity of this disease entity there is no standard 
therapy available in controlling the condition, however, 
surgical treatment, anti-osteoclastic medication and ra-
dio therapy have been suggested.  
Conclusion 
“Vanishing bone disease” also known as “Disappearing 
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bone disease” is an extremely rare bone disorder with 
no known exact etiopathogenesis. As the bones of the 
maxillofacial territory are frequently affected by this ail-
ment and due to rarity of this condition it is important 
for pediatric dentist to be aware of its occurrence as a 
rare cause of osteolysis in the maxillofacial skeleton of 
children which subsequently causing functional, cosme-
tic impairment and if untreated leading to serious com-
plications. 
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